Antioxidant may prevent, even cure, cataracts and other degenerative eye disorders

September 27, 2012
Cataract formation in rats. Top left (control lens): The lenses in this group were found to contain no detectable cataracts. Top right (BSO-only lens): All lenses in this group developed very distinct cataracts, with most being nearly completely opaque. Bottom left (NACA-only lens): Results similar to those in the control group were obtained, with no detectable signs of cataract formation. Bottom right (NACA+BSO lens): The lens depicted has a Grade 1 opacity which was evident by the amount of scattering light.

(Medical Xpress)—Researchers at Missouri University of Science and Technology are working with an antioxidant that could prevent or cure cataracts, macular degeneration and other degenerative eye disorders.

The research group, headed by Dr. Nuran Ercal, the Richard K. Vitek/Foundation for Chemical Research Endowed Chair in at Missouri S&T, is studying eye drops prepared with the antioxidant N-acetylcysteine amide (NACA) as a treatment for these eye conditions.

Ercal says NACA is an improvement over another experimental treatment, the antioxidant N-acetylcysteine (NAC), because it passes more easily across cell membranes, allowing the medication to be used in lower doses.

"NACA's characteristics as a drug were improved over NAC by neutralizing the carboxylic group of NAC, which makes the NACA pass cellular membranes easily," says Ercal. "And because NACA can be administered at a lower dose, the drug has a greater therapeutic index and lowers the risk of side effects traditionally associated with NAC.

"NACA is also an excellent source of glutathione, a cell's main antioxidant power, which is diminished during degenerative eye disorders," she adds.

Vision loss from age-related eye disorders affects more than 30 million people in the United States and is expected to double in the coming decades, Ercal says.

In addition, more than $9 billion is spent annually in the U.S. on cataract surgery alone. The total annual cost of all services related to vision problems exceeds $20 billion, she says.

"NACA eye drops could drastically reduce these costs and represent an alternative to costly surgery, while greatly improving the quality of life for those afflicted," says Ercal.

Ercal and her team have been testing NACA on HIV-related problems, lead poisoning and other toxicities for 10 years. About four years ago they began testing it on eye disorders.

Ercal recently received a $378,000 three-year research grant from the National Eye Institute of the National Institutes of Health. The preliminary data submitted for the funding was based on research by her former Ph.D. student, Joshua Carey.

Carey's dissertation involved preliminary studies of the effects of NACA to slow down cataract growth on rats that had been given L-buthionine-S,R-sulfoximine (BSO), a solution that causes to form. "The NACA solution prevented cataracts from forming," says Ercal. "Our research will build on Josh's research, to see if NACA can actually reverse the degeneration as well."

Ercal, who is also an M.D., says further testing will help establish appropriate dosage and frequency, as well as possible side effects and other factors. She says successful results using animal subjects may eventually support the viability of human usage.

Ercal works closely with Dr. Shakila Tobwala, a post-doctoral fellow in Missouri S&T's chemistry department. Others in the research group include the grant's co-investigator, Dr. Humeyra Karacal from the ophthalmology department at Washington University in St. Louis, and Missouri S&T graduate and undergraduate students.

Explore further: Novel drug to slow cataracts on their path to causing blindness

Related Stories

Novel drug to slow cataracts on their path to causing blindness

September 5, 2011
The innovators behind commercialising a world-first drug to slow cataract growth and to delay cataracts forming, have been named as one of five finalists in The University of Queensland (UQ) Business School's $100,000 Enterprize ...

Recommended for you

Novel approach to track HIV infection

August 18, 2017
Northwestern Medicine scientists have developed a novel method of tracking HIV infection, allowing the behavior of individual virions—infectious particles—to be connected to infectivity.

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.